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In spite of understanding the inception and existence of neurophobia, we are left with a question, "how to cure neurophobia in a low-resource and time-constrained settings?" First, it is mandatory to develop a concrete hour to hour objectified work plan for the neuroanatomy teaching, after taking into account the views of various stakeholders. [3] Second, a systematic review by McCarron et al. [4] offers nine solutions for curing neurophobia, the first being implementation of a team-based learning strategy with immediate feedback. In a study by Javaid et al., [5] 81.4% of participants agreed that understanding of the clinical aspects of neuroanatomy was enhanced using web-based resources and computer-assisted learning.
Based on these suggestions and banking upon the advantages of asynchronous learning, we used mobile-based learning [6] for supplemental neuroanatomy teaching. Using WhatsApp social messenger (WhatsApp Inc.) as a platform, we had divided the students into groups, contents (including 3D tutorials, clinical vignettes, annotated images, and worksheets) were circulated, and active discussion was promulgated in the presence of a moderator. The success of the modality depends on the fact that the contents delivered should be able to recruit as many cognitive domains of learning as possible. We could sense that majority of the students (78%) felt that M-learning for neuroanatomy was more effective compared to E-learning platforms, as it had offered a ubiquitous and individualized learning.
We would like to conclude that, even in settings with stringent resources and time constraints, neurophobia can be cured to an extent, provided if we use the platforms which are well acquainted to the "digital native" population. Curing neurophobia is obviously a challenge; however, as a silver lining, this challenge opens up opportunities for devising newer methodologies in medical education.
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Hereditary Spastic Paraplegia Type 35 with a Novel Mutation in Fatty Acid 2-Hydroxylase Gene and Literature Review of the Clinical Features
Sir, The hereditary spastic paraplegias (HSPs) are a heterogeneous group of neurodegenerative disorders. Few epidemiological studies of HSPs have been done to date. The estimated prevalence is 3-10 cases/100,000 population in Europe. [1] The diagnostic clinical findings are spasticity and pyramidal weakness in lower limbs, with hyperreflexia and extensor plantar responses. [2] AR HSPs are more frequent in consanguineous populations with a prevalence of 0.6/100,000 in Norway and up to 5.75/100,000 in Tunisia. [2, 3] HSP type 35 is an AR form of HSPs caused by mutations in the fatty acid 2-hydroxylase (FA2H) gene at 1`q21-q23 chromosome. [2] In the literature, a few cases have been reported with HSP type 35. [3] [4] [5] [6] Here, we report HSP type 35 case of Turkish origin with a novel homozygous mutation in FA2H gene, presented with progressive gait disturbance and cognitive impairment.
A 16-years-old boy was admitted to our hospital because of progressive difficulty in walking, unsteady gait, cognitive impairment, and hand tremor. He had normal motor and intellectual development until the age of 10 years when gait disturbance and balance problems first appeared. Five years later, he began to show deterioration in academic skills. The patient was diagnosed with cerebral palsy because of these complaints in another hospital. The parents were consanguineous, and there was no family history of neurologic disease. He was born at term and had no neonatal problems. He had healthy two older sisters. Pedigree is shown in Figure 1 .
Neurological examination revealed mild cognitive impairment and spasticity. The deep tendon reflexes were increased in lower limbs, with ankle clonus and bilateral Babinski signs. He had muscle weakness of Grade 4/5 distally in both lower limbs and had mild bilateral foot drop, pes cavus deformities, and muscular atrophy. Ophthalmologic examination and the other physical examination were normal.
Complete blood count, serum biochemistry, lipid profile, thyroid function tests, and serum Vitamin E and B12 levels were all normal. Brain magnetic resonance imaging (MRI) showed bilateral symmetrical hyperintense lesions in the periventricular white matter in T-weighted images [ Figure 2 ]. Nerve conduction studies revealed demyelinating form of polyneuropathy. Based on the clinical findings and nerve conduction studies, the patient was thought as HSP.
Clinical exome sequencing analysis was performed in the patient using TruSight One kits (Illumina Inc., San Diego, CA, USA). As a result of the clinical exome analysis, we identified a novel missense homozygous mutation at the FA2H gene (c.130C>T p. Pro44Ser p. P44S) which has not been reported previously. The mutation found was considered to be highly probable cause of disease according to in silico analysis (Sorting Tolerant From Intolerant, http://sift.jcvi. org and Mutation Taster, http://www.mutationtaster.org). Additional family screening revealed that both parents had heterozygous mutation. We confirmed that the patient was HSP type 35 due to clinical and genetically evaluation.
To date, 70 different gene loci associated with HSP were identified, involving XL, AR, AD, and maternal inheritance. [2] AR spastic paraplegia-35 (SPG35) is a characterized by childhood onset of gait difficulties due to progressive spastic paraparesis, dysarthria, and mild cognitive decline associated with leukodystrophy on brain imaging. Other variable neurologic features, such as dystonia, optic atrophy, and seizures, may also occur. [3, 4] SPG35 is caused by mutations in the FA2H gene located on chromosome 16q23. FA2H was first described in 2008 as a rare leukodystrophy gene causing spasticity and dystonia. [7] In addition, FA2H gene has been shown to be associated with neurodegeneration with brain iron accumulation, thus expanding the phenotype. This phenotypic spectrum of disorders was then referred as fatty acid hydrolase-associated neurodegeneration (FAHN). [8] FA2H gene encodes FA2H, a 372-amino-acid-long membrane-bound protein incorporated into the ceramide species which is necessary for the production of normal myelin. It contains two conserved domains, a cytochrome b5-like heme-binding domain, spanning residues 15-85 and responsible for the redox activity of FA2H, and a sterol desaturase domain at residues 210-367. [9] To date, approximately 51 patients from 19 families have been reported in the literature. [5] Cao et al. [4] reported two siblings born to nonconsanguineous parents, who possess several typical clinical features of SPG35, a subtype of FAHN, owing to novel FA2H Garone et al. [11] 7/24 -+ Optic atrophy
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Edvardson et al. [12] Rupps et al. Zaki et al. [14] 3 to 5/6 to 14 Tonelli et al. [15] 38 to 40 Pierson et al. [17] Bektaş et al. missense mutation. Two affected siblings had typical clinical features of SPG35. For the two siblings, brain MRI showed progressive leukoencephalopathy with cortical, cerebellar, and brainstem atrophy. Thinning of the corpus callosum was also noted. Soehn et al. [5] described four novel homozygous FA2H mutations in four nonconsanguineous families with SPG35. All four children presented with a complicated form of HSP with tetraspasticity and additional symptoms including limb ataxia (3/4), mild cognitive deficits (3/4), and extrapyramidal involvement (3/4). In another case, Liao et al. [3] reported three novel FA2H gene mutations in two unrelated Chinese families with SPG35. Bektaş et al. [6] described a 5-year-old boy presenting with spastic paraplegia without seizure, neuropathy, cognitive impairment, speech disturbance, and optic atrophy in Turkey. Their patient was rapid progressive spastic paraplegia, and he was early loss of ambulation. Our case had gait difficulties due to progressive spastic paraparesis, hand tremor, mild cognitive deficits, and additional findings including demyelinating form of polyneuropathy. He had no optic atrophy and cerebellar dysfunction.
Recently, identification of the neurodegeneration with brain iron accumulation expanded the phenotypic spectrum of the disorders associated with the FA2H gene mutation. [8] Brain iron accumulation was not shown in the patient.
Bektaş et al. [6] detected a novel homozygous mutation c. 160_169 dup (p. Asp57Glyfs*48) in the gene encoding FA2H in their case in Turkey. We detected novel homozygous mutation c.130C>T (p. Pro44Ser) (p. P44S) in the FA2H gene. Furthermore, the patient had demyelinating form of polyneuropathy which has not been reported in SPG35 previously. Table 1 presents the analysis of cases of SPG35 from the literature and the patient.
In conclusion, HSPs are clinically and genetically heterogeneous disorders characterized by lower limb spasticity and weakness. SPG35 should be included in the differential diagnosis of lower limb spasticity and weakness when additional ataxia, mild cognitive deficits, and extrapyramidal involvement.
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Antineutrophil Cytoplasmic Antibody Vasculitis Causing Skull Base Inflammation and Aortitis
Sir,
A 70-year-old female was admitted with sudden-onset bilateral hearing loss followed 2 weeks later by severe pain in both angles of the jaw, paresthesia of tongue, ageusia, sinonasal congestion, and vertex headache. She had a history of systemic hypertension and diabetes mellitus. On evaluation, she was afebrile and had a normal external ear canal, bilateral severe sensorineural hearing loss, and temporal bone tenderness bilaterally. Magnetic resonance imaging (MRI) showed T2 opacification with contrast enhancement of both middle-ear cavities as well as symmetric contrast enhancement of the basal and middle turns of both cochlea [ Figure 1 ]. The 7 th and 8 th nerve complex within the internal auditory canals was normal. Her erythrocyte sedimentation rate (ESR) was 105 mm/h, and P-antineutrophil cytoplasmic antibody (ANCA) by IF and anti-myeloperoxidase (MPO) by ELISA was positive (23.2 U/L).
Positron emission tomography-computed tomography (PET-CT) and three-phase bone scan showed avid uptake suggestive of inflammation in bilateral middle-ear cavities, petrous temporal bones, mastoid regions, and left torus tubarius without bone erosion [ Figure 2 ]. Fluorodeoxyglucose PET also showed circumferential wall thickening in the right brachiocephalic artery, arch of the aorta, infrarenal abdominal aorta, distal abdominal aorta, and left common iliac artery suggestive of diffuse aortitis. She refused a biopsy of the skull base lesion. Based on this, she was diagnosed with ANCA vasculitis with skull base inflammation and aortitis. She was started on intravenous methylprednisolone 1 g/day × 5 days, followed by combination therapy with oral prednisolone and mycophenolate mofetil 2 g/day for 2 months. Her hearing improved by 30 decibels and her headache resolved in 2 months. She is on maintenance immunosuppression with steroids and mycophenolate.
Skull base osteomyelitis (SBO) is a devastating condition often seen in diabetics. It presents with headache, cranial neuropathy, elevated ESR, and abnormal temporal bone or clival imaging findings. [1] Biopsy is often required for diagnosis as SBO can be caused by infection, inflammation, or malignancy. Classic malignant otitis externa occurs from spread of infection from the external auditory canal to the temporal bone, whereas central skull base osteomyelitis (CSBO) often centers on the clivus and spreads to the sphenoid or occiput. [2] CSBO is not often accompanied by external or middle-ear granulation tissue and is more indolent. CT and MRI are less useful as imaging abnormalities occur late. MRI change includes diffuse clival hypointensity on T1-weighted images relative to normal fatty marrow and pre-and paraclival soft-tissue infiltration with obliteration of normal fat planes or soft-tissue masses. 
